Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment With Recombinant Human Growth Hormone (Genotonorm®) In Children With Short Stature Secondary To A Long Term Corticoid Therapy. A Study of Efficacy and Safety.

NCT00174278 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00174278
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00174278 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment With Recombinant Human Growth Hormone (Genotonorm®) In Children With Short Stature Secondary To A Long Term Corticoid Therapy. A Study of Efficacy and Safety.
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
February 28, 1997
Completion date
October 31, 2006
Enrollment
14
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

growth hormone deficiency, growth retardation